Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).

Trial Profile

NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Acronyms NEO-RIT
  • Sponsors Wissenschaftlicher Service Pharma

Most Recent Events

  • 15 Nov 2017 Results published in the International Journal of Radiation Oncology, Biology, Physics
  • 15 Nov 2017 Status changed from active, no longer recruiting to completed, according to results published in the International Journal of Radiation Oncology, Biology, Physics.
  • 12 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top